Non-Small-Cell Lung clinical trials at UC Cancer

• A Study of Experimental Medicine Atezolizumab for Non-Small Cell Lung Cancer

  open to eligible people ages 18 years and up

  This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in patients with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) followed by open-label adjuvant atezolizumab or best supportive care and monitoring.

  at UC Davis

Last updated: October 5, 2020